Welcome to our dedicated page for Adc Therapeutics Sa news (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics Sa stock.
ADC Therapeutics SA (NYSE: ADCT) is a commercial-stage oncology company focused on antibody drug conjugates, and its news flow centers on clinical progress, regulatory developments, and corporate updates. The company’s primary product, ZYNLONTA (loncastuximab tesirine-lpyl), is a CD19-directed ADC approved under accelerated and conditional pathways for certain adults with relapsed or refractory diffuse large B-cell lymphoma after at least two prior systemic therapies.
News about ADCT commonly includes updates from its LOTIS clinical program, such as the Phase 3 LOTIS-5 trial of ZYNLONTA plus rituximab in second-line or later DLBCL and the Phase 1b LOTIS-7 trial evaluating ZYNLONTA in combination with bispecific antibodies and other agents in B-cell non-Hodgkin lymphoma. Company releases have highlighted response rates, safety findings, and enrollment milestones from LOTIS-7, as well as anticipated timelines for sharing full data and pursuing regulatory and compendia strategies.
Investors and followers of ADCT news will also find announcements on preliminary revenue and cash estimates, participation in healthcare conferences, and equity-related actions such as employee inducement grants and private placements. These items appear in both press releases and related Form 8-K filings, giving context on the company’s commercial performance and financing plans alongside its clinical pipeline.
This news page aggregates such disclosures so readers can track ADCT’s key events, from clinical trial readouts and investigator-initiated study updates in indolent lymphomas to progress on its early-stage PSMA-targeting ADC. For those monitoring ADCT stock, revisiting this page provides a consolidated view of the company’s evolving clinical, regulatory, and corporate narrative.
ADC Therapeutics (NYSE: ADCT) is set to host a conference call on August 3, 2021, at 8:30 a.m. EDT. The purpose is to discuss Q2 2021 financial results and share business updates. Investors can join via telephone or through a live webcast available on the company's website. ADC Therapeutics is focused on developing novel antibody drug conjugates for cancer treatment, with ZYNLONTA™ approved for certain lymphomas and ongoing trials for other therapies including Cami for Hodgkin lymphoma.
ADC Therapeutics (NYSE: ADCT) reported updated interim results from its ongoing Phase 2 trial of camidanlumab tesirine (Cami) in relapsed or refractory Hodgkin lymphoma at the 16th Annual ICML. The trial, aimed at supporting a Biologics License Application, includes 117 patients and shows an overall response rate (ORR) of 66.3% with 27.7% achieving complete responses. The median duration of response has not been reached. No new safety signals emerged, and treatment-related adverse events were consistent with prior phases. Cami targets heavily pre-treated patients with limited options.
ADC Therapeutics (NYSE:ADCT) announced the presentation of updated results from four clinical trials of ZYNLONTA™ (loncastuximab tesirine-lpyl) at the 16th Annual International Conference on Malignant Lymphoma (ICML). Key findings from the LOTIS-2 trial showed an overall response rate (ORR) of 48.3% and a median duration of response (mDoR) of 13.4 months in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The LOTIS-3 trial results reflected a 62.2% ORR when ZYNLONTA was combined with ibrutinib, with manageable toxicity. The company anticipates continued progress in ongoing clinical trials.
ADC Therapeutics (NYSE:ADCT) announced that shareholders approved all resolutions proposed at the Annual General Meeting (AGM). Key decisions include the election of Viviane Monges to the Board, who brings over 30 years of financial experience in the pharmaceutical sector.
The re-election of the current Board members and Compensation Committee was also confirmed, along with an increase in the maximum Board size to 12 members. Financial proposals were approved, including an increase in Authorized Share Capital by CHF 1,170,800, ensuring continued operational capacity for advancing ADC technology in cancer treatment.
ADC Therapeutics (NYSE:ADCT) announced that abstracts on camidanlumab tesirine (Cami) and ZYNLONTA™ (loncastuximab tesirine-lpyl) will be presented at the 16th Annual International Conference on Malignant Lymphoma from June 18-22, 2021. Cami's Phase 2 trial results for relapsed/refractory Hodgkin lymphoma will be shared in an oral presentation, while ZYNLONTA data will be discussed in both oral and poster formats for diffuse large B-cell lymphoma. The FDA has approved ZYNLONTA based on a notable 48.3% overall response rate in a pivotal clinical trial.
ADC Therapeutics SA (NYSE: ADCT) reported updated clinical data from the LOTIS-2 Phase 2 trial of ZYNLONTA™ for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) at the 2021 ASCO Annual Meeting. The results indicate a 48.3% overall response rate and a 24.8% complete response rate, with a median duration of response of 13.4 months. Notably, durable responses were observed in high-risk patients. No new safety concerns were identified, reinforcing ZYNLONTA's favorable safety profile. Regulatory approval from the FDA was granted based on these positive outcomes.
ADC Therapeutics (NYSE: ADCT) announced that CEO Chris Martin will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 8:30 a.m. ET. Investors can access a live webcast through the company's website, with a replay available for 30 days. ADC Therapeutics specializes in next-generation antibody drug conjugates (ADCs) for treating hematological malignancies and solid tumors. The company's FDA-approved ADC, ZYNLONTA™, targets relapsed diffuse large B-cell lymphoma, while Cami is under trial for Hodgkin lymphoma and advanced solid tumors.
ADC Therapeutics (NYSE:ADCT) announced that the Phase 1 clinical trial results of its anti-CD25 ADC, camidanlumab tesirine (Cami), have been published in The Lancet Haematology. The trial, involving 133 patients with relapsed or refractory Hodgkin and non-Hodgkin lymphomas, reported an overall response rate (ORR) of 58%, with a complete response rate of 29%. Heavily treated Hodgkin lymphoma patients showed an ORR of 71%. The study indicates Cami's potential as a treatment option for a significant unmet medical need. A pivotal Phase 2 trial is ongoing.
ADC Therapeutics SA (NYSE:ADCT) announced that three abstracts have been selected for poster presentations at the 2021 ASCO Annual Meeting, taking place virtually from June 4-8, 2021. The presentations will cover key research findings from their lead programs, highlighting the recent FDA approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) for treating relapsed or refractory large B-cell lymphoma. The FDA approval was based on a Phase 2 trial demonstrating a 48.3% overall response rate. ADC Therapeutics is advancing its pipeline of next-generation antibody drug conjugates for various cancers.
ADC Therapeutics (NYSE: ADCT) has secured a $50 million second tranche under its convertible credit facility with Deerfield Partners, following FDA's accelerated approval of ZYNLONTA™. This funding will bolster ADC Therapeutics' balance sheet and support the launch and development of its pipeline of next-generation antibody drug conjugates.
The company had previously received $65 million upon its IPO in May 2020, totaling $115 million from this facility. A Form F-3 registration statement will be filed with the SEC within 15 days, allowing Deerfield to sell shares if it opts to convert its notes.